Abstract
Captopril, an orally active dipeptide analogue was introduced in 1977 and used for the treatment of hypertension and in patients having ischaemic heart disease. Since the bioavailability of the drug is low, an alternative method to increase its bioavailability and solubility is by changing the drug in to amorphous form. We used Differential Scanning Calorimetry (DSC) for studying the glass forming ability of the drug. The sample was found to be a very good glass former. Based on the DSC analysis we have used broadband dielectric spectroscopy (BDS) for studying the drug in the super cooled and glassy state. BDS is an effective tool to probe the molecular dynamics in the super cooled and glassy state. Molecular mobility is found to be present even in the glassy state of this active pharmaceutical ingredient (API) which is responsible for the instability. The sample is highly unstable in the amorphous state and our aim is to study the factors responsible for instability of this API. Our FTIR study showed that hydrogen bonding is stronger in the amorphous state than that of crystalline state of this API. Abbreviations. API Active pharmaceutical ingredient; BDS Broadband dielectric spectroscopy; ACE angiotensinconverting enzyme; DSC Differential scanning calorimetry; FTIR fourier transform infrared spectroscopy; VFTH VogelFulcher-Tamman-Hesse. XRPD X-Ray Powder diffraction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
